Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01150890 · ClinicalTrials.gov registry record · Phase 2
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT01150890 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 130 participants.
The verdict
NCT01150890, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will know what treatment is being given.
Interventions
- DRUG Placebo
- BIOLOGICAL Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2010-11-09 |
| Est. Completion | 2011-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01150890
The ClinicalTrials.gov registry entry for NCT01150890 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01150890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01150890 about?
NCT01150890 is a clinical study titled "Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease". The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will kno...
What is the current status of trial NCT01150890?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2010-11-09. Estimated completion is 2011-10-15.
What interventions are being tested in trial NCT01150890?
The interventions under investigation include: Placebo (DRUG), Brodalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01150890?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.